Chirag Patel, MD
Allergy & Immunology · Brick, NJNPI 1891105474
Payments from drug & device makers
Across 570 payments — averaging $101.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$38K
- Alk-abello, Inc$10K
- Sanofi$3K
- Regeneron Healthcare Solutions, Inc.$976
- GSK$897
- Amgen$677
- plus $5K from 32 others
What the payments were for
- Consulting fees$1,7453%
- Speaking & faculty fees$39,49068%
- Travel & lodging$3,7106%
- Food & beverage$12,48622%
- Education$2690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 110 | $37,906 |
| Alk-abello, Inc | 12 | $9,687 |
| Sanofi | 19 | $2,606 |
| Regeneron Healthcare Solutions, Inc. | 58 | $976 |
| GSK | 62 | $897 |
| Amgen(2 entities) | 34 | $677 |
| Novartis | 60 | $664 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $599 |
| AbbVie | 30 | $575 |
| Grifols USA, LLC | 14 | $390 |
| Pfizer | 13 | $311 |
| Genentech USA, Inc. | 18 | $302 |
| CSL Behring | 9 | $270 |
| LEO Pharma Inc. | 10 | $227 |
| Incyte Corporation | 6 | $217 |
| Optinose US, Inc. | 16 | $188 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $170 |
| Kaleo, Inc. | 7 | $110 |
| Aimmune Therapeutics, Inc. | 7 | $104 |
| Covis Pharma GmbH | 8 | $102 |
| Lilly USA, LLC | 6 | $102 |
| Biocryst US Sales Co., LLC | 6 | $99 |
| Greer Laboratories, Inc. | 3 | $71 |
| Medline Industries LP | 1 | $71 |
| Boehringer Ingelheim | 4 | $59 |
| Quidel Corporation | 1 | $45 |
| Pharming Healthcare, Inc. | 2 | $38 |
| Ionis Pharmaceuticals, Inc. | 2 | $36 |
| Blueprint Medicines Corporation | 2 | $32 |
| Galderma Laboratories, L.p. | 2 | $31 |
| ADMA Biomanufacturing LLC | 2 | $26 |
| Insulet Corporation | 1 | $20 |
| Verona Pharma, Inc. | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Cycle Pharmaceuticals Inc | 1 | $13 |
| Phadia US Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$57,699 in reported general payments places this provider in the 85th percentile of 135 allergy & immunology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 142 | $551,560 |
| Dupixent PenDupilumab | 95 | $417,035 |
| XolairOmalizumab | 72 | $193,902 |
| TezspireTezepelumab-Ekko | 44 | $188,164 |
| HyqviaIgg/Hyaluronidase,recombinant | 32 | $168,045 |
| FasenraBenralizumab | 24 | $132,534 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $53,853 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 19 | $44,379 |
| Breo ElliptaFluticasone/Vilanterol | 41 | $21,276 |
| Spiriva RespimatTiotropium Bromide | 21 | $19,056 |
| Epinephrine | 44 | $13,943 |
| DuleraMometasone/Formoterol | 33 | $13,322 |
| Qvar RedihalerBeclomethasone Dipropionate | 27 | $9,061 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $8,551 |
| Azelastine Hcl | 193 | $5,189 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Fasenra, Symbicort | $37,906 | $329,24990 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Hyqvia, Gammagard Liquid | $599 | $212,42351 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $897 | $80,155118 claims |
| Boehringer IngelheimSpiriva Respimat | $59 | $19,05621 claims |
| Hikma Pharmaceuticals USAEpinephrine | $15 | $13,94344 claims |
| MerckDulera | $16 | $13,32233 claims |
| Cycle Pharmaceuticals IncCromolyn Sodium | $13 | $2,91115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 135 allergy & immunology providers in New Jersey.
Other allergy & immunology in Brick
- Bruce DecotiisBrick$647K
- Mary GeorgyBrick$10K
- Thu Thu AungBrick$9K
- Edward FernandezBrick$6K
- Ellen SherOcean$2.7M
- Andrew PedinoffSkillman$2.3M
- Patrick PerinTeaneck$589K
- Peter RickettiTrenton$501K
- Jinping GuoMarlton$488K
- Mark WeinsteinBelleville$424K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.